VINEETLAB Stock Overview
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients and fine chemicals in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Vineet Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹51.55 |
| 52 Week High | ₹88.90 |
| 52 Week Low | ₹44.65 |
| Beta | -0.32 |
| 1 Month Change | 7.17% |
| 3 Month Change | -31.08% |
| 1 Year Change | 4.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 11.58% |
Recent News & Updates
Earnings Working Against Vineet Laboratories Limited's (NSE:VINEETLAB) Share Price Following 25% Dive
Mar 07
We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt
Feb 15Shareholder Returns
| VINEETLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.7% | -2.2% | -2.1% |
| 1Y | 4.7% | 55.3% | 45.3% |
Return vs Industry: VINEETLAB underperformed the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: VINEETLAB underperformed the Indian Market which returned 45.3% over the past year.
Price Volatility
| VINEETLAB volatility | |
|---|---|
| VINEETLAB Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: VINEETLAB's share price has been volatile over the past 3 months.
Volatility Over Time: VINEETLAB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 72 | Satish Samant | vineetlabs.co.in |
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients and fine chemicals in India. It offers intermediates of lopinavir, ritonavir, efavirenz, nadolol, glimepiride, celecoxib, olanine, and other API intermediates; and fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Vineet Laboratories Limited Fundamentals Summary
| VINEETLAB fundamental statistics | |
|---|---|
| Market cap | ₹484.92m |
| Earnings (TTM) | ₹26.51m |
| Revenue (TTM) | ₹1.71b |
17.9x
P/E Ratio0.3x
P/S RatioIs VINEETLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VINEETLAB income statement (TTM) | |
|---|---|
| Revenue | ₹1.71b |
| Cost of Revenue | ₹1.32b |
| Gross Profit | ₹385.78m |
| Other Expenses | ₹359.28m |
| Earnings | ₹26.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.88 |
| Gross Margin | 22.59% |
| Net Profit Margin | 1.55% |
| Debt/Equity Ratio | 116.5% |
How did VINEETLAB perform over the long term?
See historical performance and comparison